Report Highlights

U.S. Biopsy Devices: Market Overview

The United States accounts for roughly 40 percent of global biopsy device revenue, making it the largest single national market for tissue sampling tools. Demand concentrates in breast, prostate, lung, and gastrointestinal procedures, where image-guided sampling is standard before diagnosis and treatment planning. Unlike tender-driven markets in Europe and Asia, U.S. pricing follows Medicare procedure codes and commercial payer schedules, so device economics are set by reimbursement tiers rather than government tenders.

The market is consolidated at the imaging-guided platform level but fragmented in disposable consumables. Hologic and Devicor Medical Products hold strong positions in breast biopsy systems, while needles and aspiration tools are sold across Becton Dickinson, Cook Medical, and Merit Medical Systems. Group purchasing organizations such as Vizient and Premier negotiate multi-year contracts that shape hospital adoption, so entrants must choose between competing on platforms or on high-volume consumables.

Growth Drivers in U.S. Biopsy Devices

The 2021 USPSTF update expanded lung cancer screening to adults aged 50 to 80 with a 20 pack-year history, bringing roughly 14 million Americans into eligibility. Each positive low-dose CT result triggers nodule workup, and CT-guided and navigational bronchoscopy biopsies are growing faster than legacy breast procedures as a result. Hospitals in the Medicare Advantage segment are expanding pulmonary nodule programs to meet this demand.

The FDA breast density notification rule under the Mammography Quality Standards Act took effect on September 10, 2024, requiring patients with dense breast tissue to be informed of supplemental screening options. Supplemental ultrasound and MRI screening generates additional ultrasound-guided and MRI-guided biopsies, particularly in outpatient imaging centers. Prostate biopsy practice has also shifted toward MRI-targeted sampling under PI-RADS scoring, raising demand for fusion-compatible needle systems.

Market Restraints and Entry Barriers

Most biopsy needles and guidance accessories follow the FDA 510(k) pathway, but the Quality Management System Regulation under 21 CFR Part 820 transitioned to ISO 13485 alignment effective February 2, 2026. Manufacturers without updated quality systems face audit findings and delayed shipments, which lengthens time to market. Medical Device Reporting obligations under 21 CFR Part 803 add ongoing surveillance costs for every marketed product.

Pricing pressure is the sharpest commercial barrier. Group purchasing contracts and hospital value analysis committees push disposable prices down annually, and standalone needle vendors compete against bundled platform offers. Incumbent relationships with radiologists and pathology labs are durable, so new entrants must secure clinical champions and training programs before volume commitments follow.

Market Opportunities in the United States

Lung nodule sampling offers the nearest addressable expansion, with roughly 14 million eligible screening candidates and growing navigational bronchoscopy adoption at academic and community hospitals. Vendors with CT-compatible needles and bronchoscopic tools can target this pipeline directly. Prostate MRI-targeted biopsy is a second opportunity, given that more than one million prostate biopsies are performed annually in the United States.

The shift of outpatient procedures to ambulatory surgical centers creates a third opportunity. Freestanding centers prioritize low-cost, single-use vacuum-assisted systems that reduce sterilization workload and fit lower facility payment rates. Entrants offering ASC-ready kits with bundled reimbursement support can capture share from hospital-dominated incumbents.

Market at a Glance

Leading Market Participants

• Becton, Dickinson and Company
• Hologic, Inc.
• Devicor Medical Products
• Boston Scientific Corporation
• Cook Medical
• Medtronic plc
• Olympus Corporation
• Merit Medical Systems
• Argon Medical Devices
• Teleflex Incorporated

Regulatory and Policy Environment

The FDA regulates biopsy needles and guidance systems through the 510(k) premarket notification pathway under 21 CFR Part 807, with a 90-FDA-day review goal under the Medical Device User Fee Amendments (MDUFA V, covering fiscal years 2023 to 2027). Breast imaging equipment and associated biopsy workflows fall under the Mammography Quality Standards Act, administered by FDA with CMS oversight. Manufacturers must maintain post-market surveillance under Medical Device Reporting requirements.

The Centers for Medicare and Medicaid Services sets procedure payment through the Physician Fee Schedule, which used a CY2025 conversion factor of $32.3465, and through the Ambulatory Surgical Center payment system. Pathology services are paid under the Clinical Laboratory Fee Schedule. Entrants should align clinical evidence submissions with CMS coverage determinations before launch, since coding decisions shape purchasing budgets for the following year.

Long-Term Outlook for U.S. Biopsy Devices

By 2032, the U.S. biopsy devices market is projected to reach USD 3.49 billion, growing at a 5.0 percent CAGR from the 2025 base year. Growth will concentrate in lung nodule sampling, MRI-guided prostate procedures, and supplemental breast screening follow-up. Imaging-compatible disposables will remain the primary volume driver through the forecast period.

Ambulatory surgical centers and freestanding imaging centers will hold a larger share of outpatient biopsy volume by 2032. Vendors that combine guidance platforms with reimbursement support and digital pathology integration will hold the strongest positions. Consolidation among mid-sized device makers is expected to accelerate as quality system costs rise under QMSR compliance.